Navigation Links
Latona Announces the Acquistion of Patent Rights and Orphan Drug Status to Novel Late Stage Drug Compound for Juvenile and Adult Rheumatoid Arthritis

PHOENIX, April 24 /PRNewswire/ -- Latona Life Sciences Inc. (Latona) announced today that it has entered into two agreements for the acquisition of patent rights and orphan drug status to a novel late-stage drug, trademarked "Oralgam," for the treatment of Juvenile and Adult Rheumatoid Arthritis.

Latona has entered into a licensing agreement to acquire the patent rights to Oralgam with Research Corporation Technologies, Inc., of Tucson, Arizona. Under the terms of this agreement, Latona will acquire the exclusive worldwide rights to Oralgam for the treatment of Adult Rheumatoid Arthritis and the treatment of auto-immune induced hearing loss.

Latona has also entered into a purchase and sale agreement to acquire the Orphan Drug Status, clinical data set and trademark to Oralgam with Protein Therapeutics Inc. of Tucson, Arizona. Under the terms of this agreement Latona will acquire the Orphan Drug Status to Oralgam for the treatment of Juvenile Rheumatoid Arthritis, GI Dysfunction in Autism and Dermatomyostis.

"Latona is extremely pleased to acquire the worldwide rights to Oralgam," stated Joseph Koziak, CEO of Latona. "We believe that Oralgam has the potential to provide significant relief to those who suffer from Arthritis and potential other auto-immune disorders."

About Oralgam - Oralgam is a late Phase II drug used for the treatment of immune mediated diseases. A novel product, Oralgam has shown efficacy in the treatment of juvenile arthritis in patients who have had limited success with other known pharmaceutical treatments. A platform technology, Oralgam is expected to be clinically tested in other immune mediated diseases.

About Latona Life Sciences - Latona is a privately held specialty pharmaceutical company dedicated to development and commercialization of immune mediated diseases.

About Research Corporation Technologies (RCT) - RCT ( is a technology, investment and management company that provides early stage funding and development for promising biomedical companies and technologies. RCT focuses on technology investments with origins from universities and research institutions worldwide. RCT has assets of more than $300 million to advance technology and development through venture investment partnerships and special licensing programs.

For more information:

Joseph Koziak

President and CEO

Latona Life Sciences Inc.

Ph. 480 254 8530


Michael Schultz

Vice President - Business Development

Latona Life Sciences

Ph. 314 378 2457


SOURCE Latona Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, ... organization dedicated to helping service members that have been wounded in battle and their ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/24/2016)... , June 24, 2016  Consumers have taken ... regulators/payers have placed more emphasis on patient outcomes. ... support programs in the pharmaceutical industry have evolved ... Consequently, pharmaceutical companies are focusing on becoming more ... providing products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
Breaking Medicine Technology: